Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received an average rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $19.6667.

Several brokerages recently issued reports on TVRD. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, July 8th. Wall Street Zen downgraded Tvardi Therapeutics to a “strong sell” rating in a research note on Saturday, July 18th. BTIG Research reaffirmed a “buy” rating and issued a $15.00 target price on shares of Tvardi Therapeutics in a research report on Tuesday, July 7th. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research note on Wednesday, July 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th.

Institutional Trading of Tvardi Therapeutics

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics during the 2nd quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $43,000. Headlands Technologies LLC bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $80,000. New York State Common Retirement Fund acquired a new position in shares of Tvardi Therapeutics during the second quarter worth approximately $92,000. Finally, Arax Advisory Partners boosted its position in shares of Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after buying an additional 6,173 shares during the period. 44.66% of the stock is currently owned by institutional investors.

Tvardi Therapeutics Stock Down 12.3%

TVRD opened at $2.14 on Thursday. The company’s 50-day moving average price is $2.82 and its 200 day moving average price is $3.41. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The firm has a market cap of $20.07 million, a price-to-earnings ratio of -0.69 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). Research analysts anticipate that Tvardi Therapeutics will post -2.32 earnings per share for the current year.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.